Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs

Introduction
Prostate Cancer (PCa) is the most common male malignancy in western countries and represents a major disease burden in the world. The principal problem arising from PCa is its propensity to metastasize to bone. Once tumors metastasize to bone, they are virtually the high incidence and serious consequences of skeletal metastasis of prostate cancer, the mechanism underlying this osteotropism is unclear. have suggested that endothelial progenitor cells (EPCs) residing in the bone marrow can be promote vasculogenesis of EPC at the site effect. Pristimerin, a naturally occurring quinonemethide triterpenoid compound isolated from Celastraceae and Hippocrateaceae, attracts considerable interest due to its potential 
